Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation
Primary Purpose
Atrial Fibrillation
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
DCC first then PVI
PVI then DCC after
Sponsored by
About this trial
This is an interventional other trial for Atrial Fibrillation focused on measuring AF
Eligibility Criteria
Inclusion Criteria:
- Persistent or long standing persistent AF resistant to anti-arrhythmic medication. Must have been present for more than 2 months
- Therapeutic anticoagulation for at least three weeks prior to initiation of therapy, or TEE performed prior to the procedure
- Age >= 18 years old. (Females must be either post-menopausal >12 months, practicing a protocol-acceptable method of birth control
- Scheduled for Pulmonary Vein Isolation
- Amiodarone will be stopped at least 3 months prior to procedure
Exclusion Criteria:
- Reversible causes of AF such as pericarditis, hyperthyroidism
- Presently with Valvular Heart disease requiring surgical intervention
- Presently with coronary artery disease requiring surgical intervention
- Early Post-operative AF (within three months of surgery)
- Previous MAZE or left atrial instrumentation
- Life expectancy <= 2 years
- Social factors that would preclude follow up or make compliance difficult.
- Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin
- Enrollment in another investigational drug or device study
- Patients with severe pulmonary disease
- Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction
Sites / Locations
- Cleveland Clinic
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
PVI performed in Normal Sinus Rhythm
PVI performed in Atrial Fibrillation
Arm Description
DCC first then PVI
PVI then DCC after if patient remains in Atrial Fibrillation
Outcomes
Primary Outcome Measures
Duration of procedure
Secondary Outcome Measures
Composite of duration of fluoroscopy, and radiation exposure doses
Composite of AT/AF burden and total frequency measured by event monitor, holter and/or EKG
frequency of symptomatic atrial arrhythmias measured by event monitor, holter, and/or EKG
Full Information
NCT ID
NCT02429648
First Posted
February 1, 2010
Last Updated
February 9, 2017
Sponsor
The Cleveland Clinic
1. Study Identification
Unique Protocol Identification Number
NCT02429648
Brief Title
Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation
Official Title
Timing of DCC in Patients Undergoing Pulmonary Vein Isolation Ablation (PVI) of Persistent/Permanent Atrial Fibrillation
Study Type
Interventional
2. Study Status
Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
June 2009 (Actual)
Primary Completion Date
July 2013 (Actual)
Study Completion Date
August 2015 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Cleveland Clinic
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare which strategy is superior in patients with persistent/permanent atrial fibrillation (AF) undergoing ablation, direct current cardioversion (DCC) prior to empirical pulmonary vein isolation (PVI) ; or pulmonary vein isolation (PVI)ablation in atrial fibrillation then Direct current cardioversion (DCC) if the patient remains in atrial fibrillation.
Detailed Description
Ablation of persistent/permanent Atrial Fibrillation (AF) remains a challenge. There are several strategies to improve the outcomes of persistent/permanent AF ablation. At the Cleveland Clinic one of the commonly used strategies is Direct Current Cardioversion (DCC). Depending on physician preference, patients may be ablated in atrial fibrillation then Direct current cardioverted; or Direct current cardioverted and ablated in sinus rhythm. Neither approach has been shown to be superior. As both approaches are currently being performed based on physician preference, the investigators propose to study and compare both approaches in a randomized fashion for evidence based practice.
The purpose of this study is to compare which standard of care strategy is superior in patients with persistent/permanent Atrial Fibrillation undergoing ablation, direct current cardioversion prior to empirical pulmonary vein isolation; or ablation in atrial fibrillation then direct current cardioversion if the patient remains in atrial fibrillation
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atrial Fibrillation
Keywords
AF
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
90 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PVI performed in Normal Sinus Rhythm
Arm Type
Active Comparator
Arm Description
DCC first then PVI
Arm Title
PVI performed in Atrial Fibrillation
Arm Type
Active Comparator
Arm Description
PVI then DCC after if patient remains in Atrial Fibrillation
Intervention Type
Procedure
Intervention Name(s)
DCC first then PVI
Intervention Description
DCC performed prior to PVI
Intervention Type
Procedure
Intervention Name(s)
PVI then DCC after
Intervention Description
DCC performed after PVI, if patient remains in Atrial Fibrillation
Primary Outcome Measure Information:
Title
Duration of procedure
Time Frame
day of procedure
Secondary Outcome Measure Information:
Title
Composite of duration of fluoroscopy, and radiation exposure doses
Time Frame
day of procedure
Title
Composite of AT/AF burden and total frequency measured by event monitor, holter and/or EKG
Time Frame
12 months
Title
frequency of symptomatic atrial arrhythmias measured by event monitor, holter, and/or EKG
Time Frame
12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Persistent or long standing persistent AF resistant to anti-arrhythmic medication. Must have been present for more than 2 months
Therapeutic anticoagulation for at least three weeks prior to initiation of therapy, or TEE performed prior to the procedure
Age >= 18 years old. (Females must be either post-menopausal >12 months, practicing a protocol-acceptable method of birth control
Scheduled for Pulmonary Vein Isolation
Amiodarone will be stopped at least 3 months prior to procedure
Exclusion Criteria:
Reversible causes of AF such as pericarditis, hyperthyroidism
Presently with Valvular Heart disease requiring surgical intervention
Presently with coronary artery disease requiring surgical intervention
Early Post-operative AF (within three months of surgery)
Previous MAZE or left atrial instrumentation
Life expectancy <= 2 years
Social factors that would preclude follow up or make compliance difficult.
Contraindication to the use of anti-arrhythmic medications and/or coumadin and heparin
Enrollment in another investigational drug or device study
Patients with severe pulmonary disease
Documented intra-atrial thrombus, tumor, or another abnormality which precludes catheter introduction
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Walid Saliba, MD
Organizational Affiliation
The Cleveland Clinic
Official's Role
Principal Investigator
Facility Information:
Facility Name
Cleveland Clinic
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
26857909
Citation
Bassiouny M, Saliba W, Hussein A, Rickard J, Diab M, Aman W, Dresing T, Callahan T 4th, Bhargava M, Martin DO, Shao M, Baranowski B, Tarakji K, Tchou PJ, Hakim A, Kanj M, Lindsay B, Wazni O. Randomized Study of Persistent Atrial Fibrillation Ablation: Ablate in Sinus Rhythm Versus Ablate Complex-Fractionated Atrial Electrograms in Atrial Fibrillation. Circ Arrhythm Electrophysiol. 2016 Feb;9(2):e003596. doi: 10.1161/CIRCEP.115.003596.
Results Reference
derived
Learn more about this trial
Timing of Direct Current Cardioversion (DCC) in Patients Undergoing Ablation of Persistent/Permanent Atrial Fibrillation
We'll reach out to this number within 24 hrs